Follow POL on Twitter With the debate in full swing at the moment, now is the time to catch up with Jim's analysis if you missed it in the Washington Post recently.
New featured column: Jim Copland on FDA pre-emption
Related Entries:
- Pre-Emption Issue Gets Space in WaPost
- "Four Myths about Federal Preemption of State Tort Claims"
- Sotomayor, Dabit, and preemption
- "As a policy matter we think that defibrillators are a product as to which preemption is peculiarly appropriate"
- NYU preemption symposium
- Debate on FDA preemption
- State laws to counter EFCA?
- Court sides with state-based suits against 'light' cigarettes
- "The right prescription for drug safety"
- A compromise on federal pre-emption?
- The FDA and drug pre-emption
- Georgia Supreme Court Denies Federal Pre-Emption in Thimerosal/Autism Case
- Federal regulation of the insurance industry
- Meat safety scare
 |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
 |
| Bridget Carroll Press Officer, Manhattan Institute bcarroll@manhattan-institute.org |
